Alphatec resumed with a Buy at Stifel

Stifel resumed coverage of Alphatec (ATEC) with a Buy rating and $20 price target Alphatec stood out in the firm’s U.S. spine surgeon survey as the fastest expected share gainer, giving the firm confidence in the company’s “beat-and-raise playbook,” the analyst tells investors.